Search research articles
Contact Us
Filters
Showing results (1-10 of 32) with videos related to
Page
of 4
Sort By:
Medecine Sciences : M/S
|
September 6, 2015
[Migration and pathogenicity of CD8 T cells in central nervous system diseases]
Guillaume Martin-Blondel, Béatrice Pignolet, Roland S Liblau
Annals of Neurology
|
September 5, 2017
Reply
Nicolas Fissolo, Béatrice Pignolet, David Brassat, et al.
Cellular and Molecular Life Sciences : CMLS
|
August 18, 2010
Transgenic mouse models of multiple sclerosis
Tanja Scheikl, Béatrice Pignolet, Lennart T Mars, et al.
Neurology
|
September 16, 2020
Author response: Prospective validation of the PML risk biomarker l-selectin and influence of natalizumab extended intervals
Nicholas Schwab, Tilman Schneider-Hohendorf, Béatrice Pignolet, et al.
Oncoimmunology
|
March 28, 2017
CD4+ and CD8+ T cells are both needed to induce paraneoplastic neurological disease in a mouse model
Christina Gebauer, Béatrice Pignolet, Lidia Yshii, et al.
Virology Journal
|
September 29, 2007
In vitro permissivity of bovine cells for wild-type and vaccinal myxoma virus strains
Béatrice Pignolet, Jean-Luc Duteyrat, Aude Allemandou, et al.
JCI Insight
|
April 5, 2019
IFN-γ is a therapeutic target in paraneoplastic cerebellar degeneration
Lidia Yshii, Béatrice Pignolet, Emilie Mauré, et al.
Journal of Virology
|
February 14, 2004
A virulence factor of myxoma virus colocalizes with NF-kappaB in the nucleus and interferes with inflammation
Christelle Camus-Bouclainville, Laurence Fiette, Sophie Bouchiha, et al.
Neurology(R) Neuroimmunology & Neuroinflammation
|
February 6, 2016
Therapy with natalizumab is associated with high JCV seroconversion and rising JCV index values
Nicholas Schwab, Tilman Schneider-Hohendorf, Béatrice Pignolet, et al.
Multiple Sclerosis and Related Disorders
|
August 17, 2018
Unexpected high multiple sclerosis activity after switching from fingolimod to alemtuzumab
Raphaël Bernard-Valnet, Béatrice Pignolet, Damien Biotti, et al.
Page
of 4
Search research articles
Search
Showing results (1-10 of 32) with videos related to
Sort By:
Page
of 4
Medecine Sciences : M/S
|
September 6, 2015
[Migration and pathogenicity of CD8 T cells in central nervous system diseases]
Guillaume Martin-Blondel, Béatrice Pignolet, Roland S Liblau
Annals of Neurology
|
September 5, 2017
Reply
Nicolas Fissolo, Béatrice Pignolet, David Brassat, et al.
Cellular and Molecular Life Sciences : CMLS
|
August 18, 2010
Transgenic mouse models of multiple sclerosis
Tanja Scheikl, Béatrice Pignolet, Lennart T Mars, et al.
Neurology
|
September 16, 2020
Author response: Prospective validation of the PML risk biomarker l-selectin and influence of natalizumab extended intervals
Nicholas Schwab, Tilman Schneider-Hohendorf, Béatrice Pignolet, et al.
Oncoimmunology
|
March 28, 2017
CD4+ and CD8+ T cells are both needed to induce paraneoplastic neurological disease in a mouse model
Christina Gebauer, Béatrice Pignolet, Lidia Yshii, et al.
Virology Journal
|
September 29, 2007
In vitro permissivity of bovine cells for wild-type and vaccinal myxoma virus strains
Béatrice Pignolet, Jean-Luc Duteyrat, Aude Allemandou, et al.
JCI Insight
|
April 5, 2019
IFN-γ is a therapeutic target in paraneoplastic cerebellar degeneration
Lidia Yshii, Béatrice Pignolet, Emilie Mauré, et al.
Journal of Virology
|
February 14, 2004
A virulence factor of myxoma virus colocalizes with NF-kappaB in the nucleus and interferes with inflammation
Christelle Camus-Bouclainville, Laurence Fiette, Sophie Bouchiha, et al.
Neurology(R) Neuroimmunology & Neuroinflammation
|
February 6, 2016
Therapy with natalizumab is associated with high JCV seroconversion and rising JCV index values
Nicholas Schwab, Tilman Schneider-Hohendorf, Béatrice Pignolet, et al.
Multiple Sclerosis and Related Disorders
|
August 17, 2018
Unexpected high multiple sclerosis activity after switching from fingolimod to alemtuzumab
Raphaël Bernard-Valnet, Béatrice Pignolet, Damien Biotti, et al.
Page
of 4